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Abstract
Rationale Nicotine uptake during smoking was estimated
by either analyzing the metabolites of nicotine in various
body fluids or by analyzing filters from smoked cigarettes.
However, no comparison of the filter analysis method with
body fluid analysis methods has been published.
Objectives Correlate nicotine uptake estimates between
filter analysis, salivary cotinine, and urinary excretion of
selected nicotine metabolites to determine the suitability of
these methods in estimating nicotine absorption in smokers
of filtered cigarettes.
Materials and methods A 5-day clinical study was con-
ducted with 74 smokers who smoked 1–19 mg Federal
Trade Commission tar cigarettes, using their own brands ad
libitum. Filters were analyzed to estimate the daily mouth
exposure of nicotine. Twenty-four-hour urine samples were
collected and analyzed for nicotine, cotinine, and 3′-
hydroxycotinine plus their glucuronide conjugates. Saliva
samples were collected daily for cotinine analysis.
Results Each method correlated significantly (p<0.01) with
the other two. The best correlation was between the mouth
exposure of nicotine, as estimated by filter analysis, and
urinary nicotine plus metabolites. Multiple regression
analysis implies that saliva cotinine and urinary output are
dependent on nicotine mouth exposure for multiple days.
Creatinine normalization of the urinary metabolites
degrades the correlation with mouth exposure.
Conclusions The filter analysis method was shown to
correlate with more traditional methods of estimating
nicotine uptake. However, because filter analysis is less
complicated and intrusive, subjects can collect samples
easily and unsupervised. This should enable improvements
in study compliance and future study designs.
Keywords Cigarettesmoking.Smokingbehavior.Filter.
Nicotine.Metabolites.Urine.Saliva
Introduction
A number of studies were published over the last 30 years
that attempted to determine the amount of tar and/or
nicotine that smokers receive from their cigarettes
(reviewed in Stephen et al. 1989; Pritchard and Robinson
1996; Scherer 1999). The methodology used falls into three
broad categories: (1) the analysis of biomarkers in human
body fluids or expired breath; (2) the measurement of
smoking behavior (puff volume, duration, and frequency)
followed by a smoking machine set to duplicate human
puffing conditions; and (3) the analysis of spent cigarette
filters and the calculation of smoke yields from the filter
efficiency.
Typically, biomarker measurements in blood/plasma and
smoking behavior measurements require that sampling or
measurements be made in a laboratory environment.There is
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e-mail: kstcharles@bigfoot.coma possibility that smoking behavior becomes atypical in this
type of environment (Comer and Creighton 1978; Ossip-
Klein et al. 1983).Urine,saliva,andspentcigarettefilterscan
be collected in a smoker’s everyday environment. The ana-
lysis of 24-h urine samples for nicotine and major metabolites
can provide quantitative data regarding uptake of smoke
constituents as the product is used in a smoker’se v e r y d a y
environment (see Byrd et al. 1998 and references therein for
examples).Subjectcompliancecan be anissue when trying to
determine actual cigarette yields because in an unmonitored
environment the subject must be relied upon to smoke only a
given brand, not use any other nicotine-containing products,
provide an exact accounting of every cigarette smoked during
the collection period, and collect all urinary output.
The filteranalysismethodisone ofthe least invasiveofthe
methods mentioned above. The smokers can use their product
in their normal environment and the only deviation from
normal behavior is to save the filters. Compliance is not an
issue when trying to determine the subject’s cigarette yield
because the filters from the actual cigarettes smoked are
analyzed. Inmostcases,the returnedfiltercan becomparedto
those ofthe subject’s statedbrand toassurebrand compliance.
The primary issue with this method has been that smoking
behaviorcanproducechangesinthefiltrationefficiencyofthe
filter. The filtration efficiency can vary according to the
velocity of the smoke passing through the filter and, to some
extent, the length of the tobacco rod smoked (Overton 1973;
Dwyer and Abel 1986;N o r m a ne ta l .1984). The method
used for this study was developed to minimize the effects of
smoking behavior on filter efficiency by measuring only the
portion of the filter downstream of the ventilation holes (i.e.,
the mouth end) (St.Charles 2001; Shepperd et al. 2006). This
results in relatively constant filtration efficiency over a wide
range of smoking behavior.
The objective of this study was to compare the nicotine
yield of human-smoked cigarettes (mouth exposure) as
measured by the filter analysis method and human smoke
uptake as measured by biomonitoring under strictly
controlled conditions. The biomonitoring measurements
included salivary cotinine and 24-h urinary nicotine,
cotinine, 3′-hydroxycotinine (3-HC), and their respective
glucuronide conjugates. With a good correlation between
the methods, future studies on smoker exposure can use the
simpler filter analysis method rather than resorting to
human biomonitoring techniques.
Materials and methods
Study design
The clinical portion of this study was conducted by an
independent contract research organization in 2003 (Covance
Clinical Research Unit, Madison, WI, USA). The analysis of
salivary cotinine and urinary nicotine metabolites was
performed at Covance Laboratories (Harrogate, North
Yorkshire, UK). Filter analysis was performed by the study
sponsor (Research and Development, Brown & Williamson
Tobacco Company, Macon, GA, USA). The study was
approved by Covance’s Institutional Review Board and
performed in accordance with applicable federal regulations.
Subjects who participated in the study gave their informed
consent, were told of the purpose of the study, and could
withdraw at any time.
Subject selection
Habitual smokers were recruited by Covance. Enrollment
criteria included males or nonpregnant, nonlactating
females, between 21 and 65 years of age, within −20%
to +30% of their ideal body weight, who smoked at least
15 cigarettes a day of the same cigarette brand during the
previous year. Subjects were excluded if they were under
21 years of age, were pregnant or lactating, participated in
any other clinical study within 30 days before study entry,
had a history or showed signs of a significant medical or
psychiatric condition, used prescription medications within
14 days before study entry, had a history of alcoholism or
drug addiction within a year of study entry, or used
alcohol or any nonprescription preparations within 72 h of
study entry. A few subjects deviated from the enrollment
criteria: underweight (1), overweight (5), medication or
alcohol usage before study entry (4), low cigarette
consumption (2), shortened brand loyalty duration (4),
elevated clinical chemistry (2), abdominal/hernia surgery
(7), and positive drug screen before study entry (2).
Because these deviations were considered minor and not
expected to interfere with the study objectives, the
subjects were allowed to participate in the study.
Subjects were assigned into one of four tar yield groups,
which span the range of Federal Trade Commission (FTC)
tar yields found in commercially available USA filtered
cigarettes: 1–3 mg (ULL or ultralights/low), 5–6 mg (ULH
or ultralights/high), 9–12 mg (LTS or lights), and 13–
19 mg (FF or full flavor). The purpose was to cover a wide
range of human nicotine exposure to allow robust correla-
tions between the methodologies. The goal was to enroll 20
smokers per group; however, even with additional recruit-
ment attempts, only 15 smokers enrolled in the ULL group
(market share <2%). One subject in the FF group withdrew
from the study due to illness. Table 1 summarizes the
subjects’ demographics and their respective brand charac-
teristics by tar band.
Subjects were confined to the clinic for six calendar days
to give five consecutive 24-h periods. Nine confinement
periods were staggered and limited to ten subjects or less
346 Psychopharmacology (2006) 189:345–354(generally of the same tar range group). During confine-
ment period number 8, one LTS smoker and two FF
smokers were allowed to participate with six ULL smokers
to complete the LTS and FF cells. Subjects were fed a
standardized bulk diet that excluded grilled, smoked, or
barbecued food items. Consumption of water and other
nonalcoholic beverages was unrestricted. Subjects refrained
from strenuous exercise. During confinement, subjects
smoked their usual cigarette brand ad libitum in a dedicated
smoking room equipped with ventilation and air filtration.
Use of any form of nicotine other than the subject’s
declared own brand was prohibited. Cigarettes were
purchased locally.
Urine and saliva collection and analysis
Twenty-four-hour urine samples were collected from each
subject for five consecutive days. Collections started at
approximately 0800 hours (first void excluded) and ended
at approximately 0800 hours the following day (first void
included). Urine was collected in 3-l amber plastic
containers and kept refrigerated throughout the collection
period. No chemical preservatives were used. After each
24-h sample collection, volume and pH measurements
were recorded, a sample was taken for creatinine analysis,
and 2×5-ml and 4×500-ml aliquots were taken and stored
frozen at −70°C until shipped. Aliquots were shipped
under dry ice to the analytical laboratory and stored at
−70°C until analysis.
Urinary nicotine, nicotine-N-β-glucuronide, cotinine, coti-
nine-N-β-glucuronide, trans-3′-hydroxycotinine, and trans-
3′-hydroxycotinine-O-β-glucuronide were analyzed using
solid phase extraction (SPE) and liquid chromatography
with tandem mass spectrometric detection using a method
developed and validated at the analytical laboratory (Ana-
lytical Procedure Covance no. 2002-010). Nicotine-d3,
cotinine-d3 (Sigma-Aldrich, Poole, UK), and trans-3′-
hydroxycotinine-d3 (Toronto Research Chemicals, North
York, ON, Canada) were used as internal standards. Nicotine,
cotinine (Sigma-Aldrich), trans-3′-hydroxycotinine, and the
three corresponding glucuronides (Toronto Research Chem-
icals) were used as reference standards. Samples were
incubated for 18–22 h at 37°C with β-glucuronidase, which
enzymatically deconjugated the aglycones from their respec-
tive glucuronides. The free and cleaved aglycones and their
respective deuterated internal standards were then extracted
and analyzed.
Saliva samples were collected in sterile Salivette tubes
(Sarstedt, Newton, NC, USA) from each subject for five
consecutive days at approximately 1830 hours. On day 4,
two additional saliva samples were collected at approxi-
mately 0830 and 1330 hours. Clinical staff supervised and
timed the process to assure compliance. Collected saliva
samples were immediately stored at −20°C, shipped under
dry ice to the analytical laboratory, and stored at −20°C
until analysis. Salivary cotinine was analyzed by a method
developed and validated at the analytical laboratory
(Analytical Procedure Covance no. HB-02-061) based on
a previously reported method (Bentley et al. 1999).
Filter collection and analysis
To control cigarette brand accessibility and document
cigarette consumption, cigarettes were issued by clinical
staff individually. The used filter had to be returned before
a subject received their next cigarette. Used filters were
processed under the supervision of clinical staff by having
the subject remove any tobacco particles from the used
filter before depositing it in an individually labeled glass
container. Used filters were collected for five consecutive
days with each day starting/ending at the same time as urine
samples. The filters generated daily by each subject were
shipped by overnight carrier at ambient temperature to the
analytical laboratory. Immediately upon receipt, a 10.0-mm
Table 1 Subjects’ demograph-
ics and cigarette brand charac-
teristics by tar band
Height, weight, and age are
shown as the mean (range).
Cigarette yields are shown as
the mean (SD) for the FTC
smoking method.
Subjects ULL ULH LTS FF Total
Number 15 20 20 19 74
Sex (M/F) 8/7 12/8 10/10 14/5 44/30
Height (cm) 173
(159–204)
174
(157–194)
174
(161–187)
177
(165–190)
175
(157–204)
Weight (kg) 77 (57–104) 75 (42–98) 78 (56–98) 77 (60–100) 77 (42–104)
Age 35 (21–54) 32 (21–47) 34 (21–64) 32 (21–53) 33 (21–64)
Menthol smokers 3 3 5 7 18
Brands
Menthol/nonmenthol 2/5 3/6 4/8 4/6 13/25
Tar (mg/cig) 1.4 (0.7) 5.4 (0.5) 10.1 (0.9) 15.0 (1.7) 8.3 (5.1)
Nicotine (mg/cig) 0.15 (0.05) 0.46 (0.04) 0.77 (0.06) 1.07 (0.14) 0.64 (0.34)
CO (mg/cig) 1.9 (0.9) 6.8 (0.6) 11.6 (1.4) 13.9 (2.0) 8.9 (4.6)
Puffs/cig 7.6 (0.7) 8.0 (1.1) 7.9 (1.0) 8.2 (0.9) 7.9 (1.0)
Psychopharmacology (2006) 189:345–354 347portion of the mouth end (tip) was cut from the filter using
a specially designed jig, which kept the cut-length constant
and kept a single edge razor blade perpendicular to the
filter. Tip-to-tip length variation using the jig was within
3%. The tips were stored in labeled 30-ml glass jars with
Teflon-lined lids at −20°C until analyzed.
Nicotine yields from the human-smoked cigarettes were
estimated by analyzing the tips for nicotine. Five separate
machine smoking regimes were used to provide calibration
curves for the filter tips of each brand style tested.
Cigarettes from the same batches that the subjects smoked
were used for calibration smoking. The smoking regimes
were chosen to give a wide range of cigarette yields of
approximately equal spacing. Table 2 shows the calibration
puffing conditions for each tar band. These machine puffing
regimes proved to cover the spread of human smoking
results for all but 7% of the subject-days tested (5 ULH, 1
LTS, and 6 FF out of 370 total). Six of the 12 involved
extrapolating by less than 0.1 mg of nicotine/cigarette and
the maximum extrapolation was from 2.3 to 2.6 mg/
cigarette.
Calibration equations were calculated using a linear
regression of nicotine yield as a function of tip nicotine.
These equations were then used to estimate human-smoked
cigarette yield from the measured tip nicotine. This method
was validated in a separate study using duplicated human
puffing profiles (Shepperd et al. 2006). Aging tests by the
study sponsor have shown that tip nicotine values were
constant when whole filters were stored in glass jars at
ambient temperature for up to 31 days. For this study, tips
were cut from the whole filters within 5 days.
One to nine tips per sample were extracted using either
20 or 40 ml of methanol containing 0.038 mg/ml decanol
internal standard. Tips were extracted for 40 min using a
flatbed orbital shaker at 200 rpm. All available tips were
divided into at least three separate batches, which were
extracted and analyzed on different days to average
analytical variation. For samples from days 2, 4, and 5,
extract absorbance at 310 nm was also measured to audit
the nicotine analysis using an independent method. Absor-
bance gives a measure of the tar deposited on the filter
(Sloan and Curran 1981; Shepperd et al. 2006) and we have
found that absorbance per tip correlates linearly with
nicotine per tip. For days 1 and 3, replicate vials of the
extract were stored at −20°C and subsequently analyzed for
nicotine to audit the nicotine analysis further. The root
mean square difference between the nicotine replicates was
5.5 μg/ml (7.3%). A backup set of replicate vials was kept
for use when outlying data points were identified by either
of the auditing methods. Samples were retested when they
were outside of the 95% confidence interval of the
absorbance per tip vs nicotine per tip correlation (days 2,
4, and 5) or when nicotine replicates differed by more than
20% (days 1 and 3).
The extract was analyzed for nicotine by gas chroma-
tography using an Agilent 5890 Series II with a flame
ionization detector and a J&W Scientific 30 m Megabore®
0.53 mm ID, DB-Wax (1.0 μm film) fused silica capillary
column (Agilent, Palo Alto, CA, USA). The UVabsorbance
of the extract was measured using an Ocean Optics
(Dunedin, FL, USA) PC2000 spectrometer equipped with
a fiber optic dip probe with a 2-mm path length. This gave
absorbance values within the linear range of less than 2
without further dilution. Absorbance was measured on the
same day the tips were extracted because it was found that
extract absorbance declines with even overnight storage.
Results
Measured urinary concentrations for each metabolite were
multiplied by their respective daily urine volumes and
converted based on molecular weights to yield recovery
results in nicotine equivalents. The sum of the nicotine
equivalents for nicotine, cotinine, and 3-HC were calculated
for each subject per day to give total daily urinary nicotine
equivalents (UNE) in milligrams per day. Nicotine yield per
cigarette was calculated from the mean nicotine per tip
values for each subject-day and the appropriate calibration
equation for the brand smoked. This was multiplied by the
number of cigarettes smoked by the subject that day to give
nicotine yield in milligrams per day.
This study design allowed us to achieve a wide range of
nicotine exposure suitable for the correlation of the three
methods of nicotine uptake estimation. Nicotine yield from
the human-smoked cigarettes (mouth exposure) as mea-
sured by filter analysis ranged from 3.7 to 67.1 mg/day,
UNE ranged from 3.1 to 48.4 mg/day, and saliva cotinine
ranged from 70 to 866 ng/ml. The mean (SD) proportions
of urinary metabolites, including the glucuronides, were
22% (9%) for nicotine, 35% (6%) for cotinine, and 43%
Table 2 Calibration smoking conditions by tar band
ULL ULH LTS FF
35/60/T+3/O 35/60/T+3/O 35/60/T+3/O 35/60/T+3/O
35/60/T+3/B 35/60/T+3/B 35/60/T+3/B 35/60/3 P/O
70/60/T+8/O 35/60/4 P/O 35/60/3 P/O 35/60/6 P/O
70/60/T+8/B 70/60/T+8/B 70/60/T+3/O 70/60/T+3/O
70/40/T+3/B 70/40/T+3/B 70/40/T+3/B 70/40/T+3/O
Data are presented as puff volume (ml)/puff interval (s)/length
smoked/ventilation holes
O Open, B blocked
T + # indicates overtipping plus distance (mm); # P indicates
number of puffs.
348 Psychopharmacology (2006) 189:345–354(13%) for 3-HC of the total UNE measured. When
expressed as a percentage of nicotine entering the mouth,
the proportions were 19% (9%) for nicotine, 31% (11%) for
cotinine, 39% (17%) for 3-HC, and 89% (25%) for total
nicotine equivalents.
Statistical correlations
Observed values from the three methodologies were
correlated with each other. Figure 1 shows the three plots
and correlations for all data points. Figure 1a is a graph of
the UNE vs daily nicotine yield estimated from filter
analysis; Fig. 1b shows UNE vs saliva cotinine; and Fig. 1c
shows daily nicotine yield from filter analysis vs saliva
cotinine. Linear regressions were significant for both the
slope and intercept (p<0.001) for all three correlations. The
best correlation was obtained with UNE vs daily nicotine
yield (Fig. 1a, R
2=0.66). The slope indicates that 67% of
the variation in nicotine mouth exposure calculated from
filter analysis appeared as variation in the six urinary
compounds measured. The standard error of the regression
(SER) was 4.9 mg nicotine/day. Saliva cotinine did not
correlate as well with either UNE (Fig. 1b, R
2=0.49, SER=
5.9 mg/day) or nicotine yield (Fig. 1c, R
2=0.45, SER=
7.4 mg/day). Because the amount of nicotine entering the
mouth was greater than the sum of the UNE, the standard
error of the nicotine yield would be greater than that of the
UNE due to scaling even if the correlations were
equivalent. To allow an equal comparison, the standard
error of the percent of the difference between calculated
(using the regression equation) and measured values was
calculated for the three correlations. The standard error
calculated in this manner was 32 and 42% for UNE vs
nicotine yield and saliva cotinine, respectively, and 41% for
nicotine yield vs saliva cotinine. Summary statistics for all
correlations are in Table 3.
The means of the five daily data values per subject
are shown in Fig. 2 using the same format as Fig. 1.
Again, for all correlations, the slopes and intercepts were
significant (p<0.01). The correlation for UNE vs nicotine
yield (Fig. 2a) improved significantly as shown in Table 3.
The slope increased to 0.74 while the intercept moved
closer to zero. The saliva cotinine correlations (Fig. 2b,c)
also improved, but not as dramatically as the urinary
nicotine. The correlation for UNE vs saliva cotinine
(Fig. 2b) had an R
2 value of 0.55 with a standard error of
5.3 mg/day (36%). The correlation for nicotine yield vs
saliva cotinine (Fig. 2c) had an R
2 value of 0.54 with a
standard error of 6.5 mg/day (33%).
Other findings
Although the primary purpose of this study was to
determine the statistical correlations between the three
methods of estimating nicotine uptake, data collected
during the experiment allowed for additional observations.
Creatinine normalization Normalization by urinary creati-
nine is useful when only a single or partial daily urine
collection is taken. To test the effect of creatinine
normalization, observed daily UNE were divided by their
respective millimole creatinine. A correlation was calculat-
ed with nicotine yield as the dependent variable and UNE/
mmol creatinine as the independent variable. The results are
summarized in Table 3. Both the intercept and slope are
significant (p<0.001) but normalization with creatinine
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Fig. 1 Correlations of the three methodologies (individual
measurements)
Psychopharmacology (2006) 189:345–354 349clearly degrades the correlation compared to the correlation
without normalization. The findings suggest that normali-
zation with creatinine adds another factor of variability,
which has a degrading effect on R
2, and therefore indicates
that the use of 24-h urine samples without normalization is
expected to provide more accurate results than the analysis
of partial (<24 h) urine samples with normalization. This is
in agreement with Heavner et al. (2006), who showed
mechanistically that creatinine normalization may be
appropriate for some, but not all, of the urinary metabolites
of nicotine and that other methods of normalization may be
more appropriate for spot urine samples.
FTC smoke yields Because this was a confined clinical
study, subjects would not necessarily be expected to behave
as if they were in their normal environment. However,
because a wide range of FTC cigarette yields were tested, it
was considered worthwhile to test the correlation between
the measured FTC yields and the three methods of nicotine
estimation. Correlation results are summarized in Table 3
for the 5-day mean values for the three methods vs the FTC
values on a per subject basis. All correlations gave
significant slopes and intercepts (p<0.001).
Differences between tar band groupings The results for
mouth exposure to nicotine (from filter analysis), UNE,
saliva cotinine, and cigarettes smoked per day were
grouped by tar band and the mean, standard deviation,
and one-way analysis of variance (ANOVA) were calculat-
ed on a per subject basis (Altman and Bland 1997). The
results are shown in Table 4. Group means increased in
rank order with increasing group yield except for saliva
cotinine and cigarettes smoked per day. All measurements
except cigarettes smoked per day gave a significant (p<0.05)
effect of group by ANOVA. For each measurement, results
with different letter assignments are significantly different at
the 95% confidence level (Fisher test). Normalizing urinary
nicotine metabolites with creatinine resulted in an increase in
p value for effect of group and no significant differences
between the FF, LTS, and ULH groups. All three groups
were significantly higher than the ULL group. This again
shows that creatinine normalization degrades the discrimi-
nating power.
Self-reported vs actual cigarette usage Table 4 also shows
the difference in self-reported and measured cigarette
usage. Self-reported cigarette usage was questioned and
compliance with respect to truthfulness can be a concern
(Byrd et al. 1998). In this study, subjects were asked to
estimate their cigarette usage as part of the recruiting pro-
cess. This gave a basis to compare with the measured usage
during the study (overall mean=22 cigarettes/day, SD=4.2,
range 15.8 to 32.0). The mean value for the (5-day average−
self-reported) usage per subject was −0.2 cigarettes/day
(SD=5.9, range −19.4 to +11.7). Even when broken down
to the smaller tar band groups of 15 to 20 subjects, the mean
difference in measured and reported usage was less than
2 cigarettes/day.
Within-subject variation Because the trial took place over
five consecutive days, within-subject, day-to-day variation
was calculated for each of the measured variables. In
addition, on day 4, saliva samples were taken at approxi-
mately 0830, 1330, and 1830 hours for measurement of
saliva cotinine to estimate within-day variation. Results are
summarized in Table 5 and are expressed as a pooled (root-
mean-squared) coefficient of variation. The pooled day-to-
day variations for each variable were similar, ranging from
Table 3 Summary of the sta-
tistics for linear correlations
Urine Urinary nicotine equiv-
alents, Filter daily nicotine
yield estimated from filter
analysis, Saliva saliva cotinine
concentration, FTC FTC nico-
tine yield, CI confidence
interval
Correlation (y : x) Intercept
(95% CI)
Slope
(95% CI)
R
2 Standard error (%)
Urine : filter Individual 4.3 (1.2) 0.67 (0.05) 0.66 4.9 (32)
mg/day : mg/day Average 2.7 (2.0) 0.74 (0.08) 0.83 3.2 (21)
Urine : saliva Individual 5.8 (1.6) 0.042 (0.004) 0.49 5.9 (42)
mg/day : ng/ml Average 5.4 (3.2) 0.043 (0.009) 0.55 5.2 (36)
Filter : saliva Individual 6.9 (2.0) 0.048 (0.006) 0.45 7.4 (41)
mg/day : ng/ml Average 5.6 (4.0) 0.052 (0.011) 0.54 6.5 (33)
Filter : urine (creatinine normalized) Individual 8.7 (1.9) 10.8 (1.3) 0.42 7.6 (41)
mg/day : mg/day/mmol creatinine Average 7.1 (3.9) 12.1 (2.7) 0.52 6.7 (32)
Urine : FTC
mg/cig : mg/cig Average 0.49 (0.13) 0.66 (0.19) 0.41 0.27 (42)
Filter : FTC
mg/cig : mg/cig Average 0.52 (0.17) 0.85 (0.24) 0.41 0.35 (38)
Saliva : FTC
ng/ml : mg/cig Average 211 (58) 184 (81) 0.22 119 (46)
350 Psychopharmacology (2006) 189:345–35415.2% for cigarettes smoked per day to 18.1% for UNE per
day. The within-day variation of 8.1% for saliva cotinine
was approximately half the day-to-day variation of 15.7%.
When a single factor ANOVA was calculated using saliva
cotinine for the three time periods sampled on day 4, the
variation between time periods was insignificant (p=0.58).
However, this could have been overwhelmed by the subject-
to-subject variation in nicotine uptake. This factor was
removed by dividing the individual measurement by the
daily average per subject for all three time periods. A single
factor ANOVA was significant for time of day (p<0.001)
with the mean (95% confidence interval) saliva cotinine
values being 1.008 (0.015), 0.96 (0.012), and 1.03 (0.013)
times the average daily value per subject for the 0830,
1330, and 1830 hour samples, respectively. Even though
the time of day had a statistically significant effect, the
practical differences were small.
Discussion
All three of the estimation methods correlated significantly
with each other, but the best overall correlation was
between the filter analysis method and UNE. The slopes
for the correlations of UNE as a function of mouth
exposure to nicotine were 0.67 and 0.74 for the individual
and 5-day average regressions, respectively, implying that
about 70% of the difference in the UNE measured in this
study was due to a difference in mouth exposure to
nicotine. However, the mean of the total UNE expressed
as a percentage of the nicotine entering the mouth was
89%. The mean value falls within the reported range of
80% (Benowitz et al. 1994) to 90% (Curvall et al. 1991) but
the slopes fall below this range. The difference between the
two methods is due to the significant intercept calculated
using the linear regression. The intercept using the 5-day
Table 4 Mean±SD for mea-
surements grouped by tar band
Results with different letters
are significantly different at the
95% confidence level
ULL ULH LTS FF ANOVA p
No. of subjects 15 20 20 19 –
Mouth exposure
(mg nicotine/cigarette)
0.63±0.18a 0.94±0.29b 1.19±0.33c 1.37±0.58c <0.0005
Mouth exposure
(mg nicotine/day)
14.7±5.6a 22.0±7.1b 24.4±6.4bc 28.3±12.6c <0.0005
Urinary nicotine (mg/cigarette) 0.59±0.19a 0.84±0.27b 0.96±0.21b 1.20±0.41c <0.0005
Urinary nicotine (mg/day) 13.6±5.7a 19.3±6.8b 19.8±5.9b 24.5±8.9c <0.0005
Creatinine normalized urinary
nicotine (mg/day/mmol)
0.93±0.58a 1.31±0.51ab 1.43±0.58b 1.45±0.52b 0.040
Saliva cotinine (ng/ml) 216±107a 347±119bc 314±88b 411±149bc <0.0005
Cigarettes/day 22.8±4.7a 23.4±3.6a 21.2±4.5a 20.8±4.2a 0.190
Cigarettes/day
(self-reported minus measured)
1.6±5.1 1.0±8.0 0.9±5.4 0.1±5.9
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Fig. 2 Correlations of the three methodologies (5-day average per
subject)
Psychopharmacology (2006) 189:345–354 351average results was lower than the intercept using the
individual results and the slope was greater. The intercept
could represent compartmental nicotine and/or metabolite
storage with subsequent carryover from storage before
entering the study. This influence should diminish with a 5-
day average compared to using single day results. An
example of this is demonstrated in Fig. 1a where there is a
single circled data point that appears to be an outlier.
Urinary output of nicotine equivalents was approximately
two times the mouth exposure of nicotine for that day.
However, this was a day 1 measurement for a single
subject. For subsequent days, the data points for this subject
are buried within all the other data points. One possibility is
that the subject had a much larger exposure to nicotine
before participating in the study and the unusually high
urinary output was due to clearance of the prior exposure.
Averaging the results over 5 days would take out much of
the metabolic influence and result in a much better
correlation as demonstrated with these results.
For the saliva cotinine correlations, the R
2 values only
improved slightly with averaging. Part of the reason for the
improvement with all correlations can be attributed to
averaging out measurement variation. This should be
similar for all correlations. However, the additional im-
provement in the filter vs urine correlation can be explained
by metabolism. Nicotine has a relatively short serum
elimination half-life of 2.2–2.9 h (Scherer et al. 1988;
Benowitz and Jacob 1993; Benowitz et al. 1999, 2002,
2004), which means that the urinary nicotine should be
from the nicotine taken in that day. Cotinine has a serum
elimination half-life typically reported at 16–18 h (Scherer
et al. 1988; Benowitz et al. 1999, 2002, 2004; De Schepper
et al. 1987) and a similar urine elimination half-life
(Benowitz and Jacob 1993; De Schepper et al. 1987). 3-
HC, which is downstream metabolically from cotinine, has
a serum elimination half-life of 5.9–6.6 h with a similar
urine elimination half-life (Scherer et al. 1988; Benowitz
and Jacob 2001). Given the pharmacokinetic information,
these urinary metabolites must have originated from
nicotine exposure on multiple days as has been demon-
strated directly using nicotine infusion (Scherer et al.
1988).
Because measurements were taken over sequential days
of input (filter analysis), the temporal source of urinary and
salivary metabolites could be estimated by multiple
regression of the metabolites vs the daily nicotine exposure.
This analysis was performed using the nicotine exposure
for the current day and the two previous days according to
the equation:
Metabolite ¼ Intercept þ b   N   2 ðÞ þ c   N   1 ðÞ þ d
  N ðÞ ;
where (N), (N-1), and (N-2) equals the nicotine exposure
for the current day, 1 day before, and 2 days before the
urine or saliva sample, respectively. Metabolite measure-
ments from days 3, 4, and 5 were used. None of the
coefficients for nicotine exposure from 2 days before the
urine collection were significant (p>0.15). For saliva
cotinine, the coefficient for 2 days before was not
significant at the 95% confidence but the p value of 0.07
was small enough to warrant consideration. Given this, the
regressions were recalculated using (N) and (N-1) and
including the urinary metabolite measurements from day 2
as well. The results of this regression are shown in
Table 6.
For the sum of all urinary metabolites, the coefficients
were significant for the current day and prior day’s
exposure. This implies that the total urinary metabolites
originated from nicotine exposure over 2 days. The only
coefficient that was significant for the urinary nicotine
regression was for the current day’s exposure as would be
expected. The coefficient of 0.16 implies that 16% of the
nicotine entering the mouth appeared as urinary nicotine
plus the glucuronide. This agrees closely with the estimates
of 13.8% (Benowitz et al. 1994) and 10–15% (Curvall et al.
1991). For the urinary cotinine regression, coefficients for
Table 6 Multiple regression
results for source of urinary
and salivary metabolites as a
function of nicotine exposure
from current and previous day
Results expressed as regression
coefficient (p value)
Coefficient Sum of urinary Urinary nicotine Urinary cotinine Urinary
3-HC
Salivary cotinine
R
2 0.72 0.40 0.64 0.42 0.50
Intercept 3.51 (<0.001) 0.77 (<0.01) 0.85 (<0.01) 1.89 (<0.001) 97.9 (<0.01)
Previous day 0.24 (<0.001) 0.004 (0.89) 0.08 (<0.01) 0.16 (<0.001) 5.7 (<0.01)
Current day 0.46 (<0.001) 0.16 (<0.001) 0.18 (<0.01) 0.12 (<0.01) 4.2 (<0.01)
Table 5 Within-subject variation expressed as a pooled coefficient of
variation (CV)
Analyte Type Pooled CV (range)%
Filter (nicotine yield/day) Day-to-day 16.7 (6–36)
Urine (nicotine equiv./day) Day-to-day 18.1 (4–54)
Saliva cotinine concentration Day-to-day 15.7 (4–47)
Saliva cotinine concentration Within-day 8.1 (0.8–16)
Cigarettes/day Day-to-day 15.2 (3–36)
352 Psychopharmacology (2006) 189:345–354the current day and previous day were significant with the
current day being about twice that of the previous day.
The two coefficients imply that 26% of the nicotine
entering the mouth appears as urinary cotinine plus the
glucuronide. This also agrees closely with estimates of
25.6% (Benowitz et al. 1994) and 20–25% (Curvall et al.
1991). For the 3-HC regression, the coefficients for the
current day and previous day were significant with the
current day being slightly smaller than the previous day.
The sum of the coefficients (0.28) was smaller than the
reported 41 to 60% of the total urinary metabolites
(Benowitz et al. 1994; Curvall et al. 1991). It is possible
that because 3-HC is the third step in the metabolism of
nicotine, there was too much of a smoothing effect for the
change in daily mouth exposure to fully capture.
For saliva cotinine, all coefficients were significant,
suggesting that saliva cotinine results are an amalgam of at
least 2 days of nicotine exposure. Saliva cotinine correla-
tions suffer because results are expressed as concentration
rather than an absolute value, and as such can be influenced
by body size. In addition, other variables come into play
that are not easily explained. An example of this is shown
in Figs. 1 and 2 by the data points with boxes around them.
These were from one subject that appeared to have
unusually low saliva cotinine values for both UNE
(Figs. 1ba n d2b) and mouth exposure of nicotine
(Figs. 1c and 2c). This subject had the highest mouth
exposure of nicotine of all the subjects studied, yet the
saliva cotinine values were only slightly above midrange.
There was nothing unusual about this subject and average
urinary output was within 1 SD (1,100 ml) of the average
for all subjects (2,400 ml). It is unlikely that nicotine yields
were overestimated because Fig. 1a shows that the data
points are scattered about the regression line for UNE vs
nicotine yield. It is also unlikely that the saliva cotinine
concentrations were in error because the saliva cotinine for
each day was analyzed in separate batches along with other
samples. The subject did not rapidly metabolize cotinine to
3-HC because cotinine accounted for 47% of the urinary
metabolites measured for this subject compared to an
average of 35% for all subjects indicating the converse.
Therefore, it must be concluded that this is an anomaly
characteristic of this individual.
As shown in Table 3, with many of the estimation
methods, the correlations are only slightly better than
simply correlating with FTC nicotine yield of the cigarette.
The average nicotine mouth exposure, as measured by the
filter method, correlated with the FTC nicotine yield with a
standard error of 38% and an R
2 value of 0.41. The
correlation of nicotine mouth exposure with saliva cotinine
gave a standard error of 33% and creatinine-normalized
urinary metabolites gave a standard error of 32% with R
2
values approximately 0.1 higher.
Correlations of FTC nicotine with biomarkers in this
study were stronger than that reported in other studies (Byrd
et al. 1998;J a r v i se ta l .2001;U e d ae ta l .2002; Hecht et al.
2005; Bernert et al. 2005). We believe that there are valid
reasons for this. One is that the correlations were performed
using the 5-day averages per subject instead of a single
sample per subject. In addition, exact compliance to brand
and cigarette consumption was assured in the current study,
whereas all but one (Bernert et al. 2005) of the referenced
studies used self-reported brand identification and cigarette
consumption. Self-reported brand information was reported
to have about a 25% error rate when compared with packs
returned (Peach et al. 1986) or in a test–retest comparison
(Eisenhower et al. 1993). This and the potential for use of
alternate brands during a study can further confound a
correlation with biomarkers. Other confounding factors are
the use of creatinine normalized spot urine samples instead
of 24-h urine samples and analyzing for a subset of the
nicotine metabolites used in the current study. Simple
creatinine normalization is only biologically valid for xeno-
biotics that have the same excretion mechanism and urinary
flow rate dependence as creatinine. Heavner et al. (2006)
have shown that 1-HC (free and glucuronide) and cotinine
glucuronide have urinary flow rate dependence similar to
creatinine while nicotine (free and glucuronide), free
cotinine, 1-hydroxypyrene, and the free and glucuronide
forms of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol do
not.
In conclusion, two methods stand out as superior. One is
the filter method, which estimates mouth level exposure
directly on a per cigarette basis. Filter collection need not be
quantitative, the filter returned can be compared to the brand
it is supposed to be and it can be readily determined if it was
smoked or not. Thus, brand compliance and smoking status
can be assured even if the subject happened to occasionally
use a different brand or other form of nicotine during the
study. With self-reported daily cigarette use from groups of
at least 15–20 subjects, the exposure per cigarette can be
converted accurately to daily exposure. In addition, mouth
exposure to tar can also be estimated using the filter method
(Shepperd et al. 2006). The other measurement, which is
considered by many to be the “gold standard,” is the
measurement of urinary nicotine and metabolites from
24-h urine samples without creatinine normalization. This
method appears to reflect the mean daily nicotine uptake
of the last 2 days.
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